Investigating the effect of metformin on the activity of systemic lupus erythematosus

Investigating the effect of metformin on disease activity in systemic lupus erythematosus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220817055730N1

Enrollment

Registered

2022-10-08

Start date

2022-09-18

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic lupus erythematosus. Systemic lupus erythematosus, unspecified

Interventions

Intervention 1: Intervention group: a group of 32 patients with systemic lupus erythematosus, in addition to the routine treatments of this disease (such as:prednisolone ,hydroxychloroquine,methotrexa

Eligibility

Sex/Gender

All

Age

19 Years to No maximum

Inclusion criteria

Inclusion criteria: suffering from Systemic lupus erythematosus disease Age above 18 years

Exclusion criteria

Exclusion criteria: Kidneys involvement Central Nervous System involvement Heart failure Hepatic failure pregnancy Breast feeding Alcohol consumption Metformin use due to Diabetes mellitus

Design outcomes

Primary

Measure	Time frame
ESR rate. Timepoint: before the start of the study and three months after its start. Method of measurement: It is measured with ESR analyzer by Western green method.;Arthritis. Timepoint: before the start of the study and three months after its start. Method of measurement: Detailed examination by a rheumatologist for the presence of warmth, sensitivity, swelling or effusion.;Skin rash. Timepoint: before the start of the study and three months after its start. Method of measurement: Skin examination by a rheumatologist for the presence of acute, sub-acute and chronic inflammatory skin rash specific to lupus.;Hair loss. Timepoint: before the start of the study and three months after its start. Method of measurement: With the pull test method.;Mucosal ulcer. Timepoint: before the start of the study and three months after its start. Method of measurement: Examination of the nose and mouth to check for the presence of ulcers.;Fever. Timepoint: before the start of the study and three months after its start. Method of measurement: Mercury thermometer.;Pleurisy. Timepoint: before the start of the study and three months after its start. Method of measurement: Lung auscultation and lung CT scan if necessary.;Pericarditis. Timepoint: before the start of the study and three months after its start. Method of measurement: Auscultation of the heart ; ECG or echocardiography.;Complements: C3,C4,CH50. Timepoint: before the start of the study and three months after its start. Method of measurement: by the ELIZA method.;Anti- ds DNA. Timepoint: before the start of the study and three months after its start. Method of measurement: by ELIZA method, IF.;Platelet. Timepoint: before the start of the study and three months after its start. Method of measurement: Cell counter machine.;White blood cell. Timepoint: before the start of the study and three months after its start. Method of measurement: Cell counter machine.;SLEDAI scoring based on physical examination and laboratory data. Tim	—

Measure

Time frame

ESR rate. Timepoint: before the start of the study and three months after its start. Method of measurement: It is measured with ESR analyzer by Western green method.;Arthritis. Timepoint: before the start of the study and three months after its start. Method of measurement: Detailed examination by a rheumatologist for the presence of warmth, sensitivity, swelling or effusion.;Skin rash. Timepoint: before the start of the study and three months after its start. Method of measurement: Skin examination by a rheumatologist for the presence of acute, sub-acute and chronic inflammatory skin rash specific to lupus.;Hair loss. Timepoint: before the start of the study and three months after its start. Method of measurement: With the pull test method.;Mucosal ulcer. Timepoint: before the start of the study and three months after its start. Method of measurement: Examination of the nose and mouth to check for the presence of ulcers.;Fever. Timepoint: before the start of the study and three months after its start. Method of measurement: Mercury thermometer.;Pleurisy. Timepoint: before the start of the study and three months after its start. Method of measurement: Lung auscultation and lung CT scan if necessary.;Pericarditis. Timepoint: before the start of the study and three months after its start. Method of measurement: Auscultation of the heart ; ECG or echocardiography.;Complements: C3,C4,CH50. Timepoint: before the start of the study and three months after its start. Method of measurement: by the ELIZA method.;Anti- ds DNA. Timepoint: before the start of the study and three months after its start. Method of measurement: by ELIZA method, IF.;Platelet. Timepoint: before the start of the study and three months after its start. Method of measurement: Cell counter machine.;White blood cell. Timepoint: before the start of the study and three months after its start. Method of measurement: Cell counter machine.;SLEDAI scoring based on physical examination and laboratory data. Tim

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNoushin Movafagh

Ahvaz University of Medical Sciences

movafagh-n@ajums.ac.ir+98 61 3320 4504

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026